Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 768540, 7 pages
http://dx.doi.org/10.1155/2014/768540
Research Article

Treatment of Nonalcoholic Fatty Liver Disease with Total Alkaloids in Rubus aleaefolius Poir through Regulation of Fat Metabolism

1Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian 361009, China
2Jinshan Street Community Health Service, Xiamen, Fujian 361000, China
3Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China
4Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, China
5Department of Integrative Medicine, Fuzhou, Fujian 350122, China

Received 5 May 2014; Accepted 7 August 2014; Published 14 October 2014

Academic Editor: I-Min Liu

Copyright © 2014 Ying Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Clark, F. L. Brancati, and A. M. Diehl, “Nonalcoholic fatty liver disease,” Gastroenterology, vol. 122, no. 6, pp. 1649–1657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. C. A. Matteoni, Z. M. Younossi, T. Gramlich, N. Boparai, and A. J. McCullough, “Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity,” Gastroenterology, vol. 116, no. 6, pp. 1413–1419, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. E. M. Brunt, C. G. Janney, A. M. Di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions,” The American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467–2474, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. N. M. W. de Alwis and C. P. Day, “Non-alcoholic fatty liver disease: the mist gradually clears,” Journal of Hepatology, vol. 48, pp. S104–S112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. C.-H. Chen, M.-H. Huang, J.-C. Yang et al., “Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults,” Journal of Clinical Gastroenterology, vol. 40, no. 8, pp. 745–752, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Bellentani, G. Saccoccio, F. Masutti et al., “Prevalence of and risk factors for hepatic steatosis in Northern Italy,” Annals of Internal Medicine, vol. 132, no. 2, pp. 112–117, 2000. View at Google Scholar · View at Scopus
  7. L. Shen, J.-G. Fan, Y. Shao et al., “Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey,” World Journal of Gastroenterology, vol. 9, no. 5, pp. 1106–1110, 2003. View at Google Scholar · View at Scopus
  8. P. Angulo, “Nonalcoholic fatty liver disease,” The New England Journal of Medicine, vol. 346, pp. 1221–1231, 2002. View at Publisher · View at Google Scholar
  9. A. J. McCullough, “Update on nonalcoholic fatty liver disease,” Journal of Clinical Gastroenterology, vol. 34, no. 3, pp. 255–262, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. A. K. Saha and N. B. Ruderman, “Malonyl-CoA and AMP-activated protein kinase: an expanding partnership,” Molecular and Cellular Biochemistry, vol. 253, no. 1-2, pp. 65–70, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-F. Ji, X.-J. Li, and H.-Y. Zhang, “Natural products and drug discovery,” EMBO Reports, vol. 10, no. 3, pp. 194–200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Q. Shi, Y. C. Fan, W. Y. Liu et al., “Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis,” Molecular Biology Reports, vol. 39, no. 10, pp. 9715–9722, 2012. View at Publisher · View at Google Scholar
  13. Z.-F. Hong, T.-J. Li, and J.-Y. Zhao, “Effect of total alkaloids of Rubus alceaefolius poiron on gene expressions of CYP2E1 and CYP3A1 in rats with acute liver injury,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 29, no. 8, pp. 711–715, 2009. View at Google Scholar · View at Scopus
  14. J. Lin, J. Zhao, T. Li, J. Zhou, J. Hu, and Z. Hong, “Hepatoprotection in a rat model of acute liver damage through inhibition of CY2E1 activity by total alkaloids extracted from Rubus alceifolius poir,” International Journal of Toxicology, vol. 30, no. 2, pp. 237–243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. H. L. Bonkovsky, Q. Jawaid, K. Tortorelli et al., “Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 31, no. 3, pp. 421–429, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. E. M. Brunt, “Steatohepatitis: pathologic features and differential diagnosis,” Seminars in Diagnostic Pathology, vol. 22, no. 4, pp. 330–338, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Postic and J. Girard, “Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice,” Journal of Clinical Investigation, vol. 118, no. 3, pp. 829–838, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Angulo, “GI epidemiology: nonalcoholic fatty liver disease,” Alimentary Pharmacology & Therapeutics, vol. 25, no. 8, pp. 883–889, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J. B. Dixon, P. S. Bhathal, and P. E. O'Brien, “Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese,” Gastroenterology, vol. 121, no. 1, pp. 91–100, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Marchesini, M. Brizi, G. Blanchi et al., “Nonalcoholic fatty liver disease: a feature of the metabolic syndrome,” Diabetes, vol. 50, no. 8, pp. 1844–1850, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. A. K. Saha and N. B. Ruderman, “Malonyl-coa and AMP-activated protein kinase: an expanding partnership,” Molecular and Cellular Biochemistry, vol. 253, no. 1-2, pp. 65–70, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Ruderman and M. Prentki, “AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome,” Nature Reviews Drug Discovery, vol. 3, no. 4, pp. 340–351, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Bartlett and S. Eaton, “Mitochondrial β-oxidation,” European Journal of Biochemistry, vol. 271, no. 3, pp. 462–469, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. W.-N. Cong, R.-Y. Tao, J.-Y. Tian, G.-T. Liu, and F. Ye, “The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice,” Life Sciences, vol. 82, no. 19-20, pp. 983–990, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Saggerson, “Malonyl-CoA, a key signaling molecule in mammalian cells,” Annual Review of Nutrition, vol. 28, pp. 253–272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. D. L. Cinti, L. Cook, M. N. Nagi, and S. K. Suneja, “The fatty acid chain elongation system of mammalian endoplasmic reticulum,” Progress in Lipid Research, vol. 31, no. 1, pp. 1–51, 1992. View at Publisher · View at Google Scholar · View at Scopus